LYMARIE VILELLA: Open Payments
NPI 1205280484 · GROVELAND, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,013 in 225 payments from 18 companies in 2025. Trend: 2023 $4,645 · 2024 $2,795 · 2025 $4,013
Food & beverage: $4,013
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 43 | $681 |
| Neurocrine BioSciences, Inc. | 23 | $524 |
| E.R. Squibb & Sons, L.L.C. | 15 | $316 |
| Collegium Pharmaceutical, Inc. | 20 | $316 |
| Corium, LLC | 12 | $247 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $235 |
| Axsome Therapeutics, Inc. | 8 | $210 |
| Vanda Pharmaceuticals Inc. | 8 | $199 |
| Supernus Pharmaceuticals, Inc. | 17 | $190 |
| Otsuka America Pharmaceutical, Inc. | 11 | $188 |
Products named: VRAYLAR, INGREZZA, COBENFY, Jornay PM, Azstarys, CAPLYTA, Auvelity, REXULTI.
Industry payments across FL — which companies pay providers there.
